GC Biopharma Revises Brazil Supply Contract Value to KRW 142.12 Billion
Bitget2026/11/02 01:37- GC Biopharma raised its Brazilian supply contract with BLAU Farmaceutica to KRW 142.12 billion from KRW 121.96 billion in a November 2 correction.
- The revised amount includes finalized 2026 sales and estimated first-quarter 2027 supplies, representing 8.3% of 2022 consolidated revenue.
- Supply volumes from the second quarter of 2027 through the contract’s June 29, 2028 expiration remain unconfirmed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
